Mediterranean-style diet for children with juvenile arthritis
Official title: The Role of Diet, as Mediated by the Gut Microbiome, on Childhood Arthritis Disease Activity: a Feasibility Intervention Study
Run by The Hospital for Sick Children · NCT06474546 · Data updated 2026-11-12
This study will try a Mediterranean-style diet in children aged 8–18 with juvenile idiopathic arthritis to see if it improves arthritis symptoms and changes the gut microbiome.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years to 18 Years |
| Sex | All |
| Enrollment | 54 (estimated) |
| Sponsor | The Hospital for Sick Children Academic / other |
| Locations | 7 sites (Winnipeg, Manitoba and 6 other locations) |
| Status | Recruiting |
| Started | April 7, 2025 |
| Main results expected | August 2028 |
| Study ends | October 2028 |
| Registry record updated | July 29, 2026 |
| Trial ID | NCT06474546 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 8–18 with juvenile idiopathic arthritis (excluding systemic JIA, enthesitis-related arthritis, and RF-positive polyarthritis) who are on stable medications, fluent in English or French, and willing to provide stool samples and follow diet instructions.
✕Probably not a fit
Children with excluded JIA subtypes, documented food allergies or celiac disease, or major comorbidities that affect diet (such as type 1 diabetes) are unlikely to be eligible and would not be expected to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Fifty-four children with juvenile idiopathic arthritis will follow a Mediterranean-style diet for an 8-week period with an optional additional 4-week extension. Stool and blood samples, diet and lifestyle questionnaires, and clinician disease assessments will be collected at baseline, 8 weeks, and 12 weeks. The study will compare clinical disease measures and microbiome composition over time to see whether diet-related microbiome changes accompany any symptom improvements. Eligible participants must be 8–18 years old, fluent in English or French, on stable treatment, and without specific food allergies, celiac disease, or major comorbidities that would affect diet tolerance.
Why it matters
Potential benefit: If successful, the diet could reduce arthritis symptoms and improve gut health, offering a low-risk, non-drug option to complement current treatments.
How similar studies have gone: Prior research in adults and some pediatric work has shown Mediterranean-style diets can reduce inflammation and alter the gut microbiome, but randomized data specifically in juvenile idiopathic arthritis are limited, so this approach is promising but not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 8-18 years * Diagnosis of JIA (excluding systemic JIA, enthesitis-related arthritis, and rheumatoid factor (RF) positive polyarthritis) as per International League of Associations for Rheumatology (ILAR) criteria. (For this feasibility study, there will be no requirement for any particular level of disease activity.) * Subjects on stable treatment - i.e., any medical treatment with disease-modifying antirheumatic drugs (DMARDs) and/or systemic or intraarticular corticosteroids, has been unchanged for 8 weeks, and is unlikely to change for 12 weeks as judged by the treating physician. * Willingness to provide stool samples. * English or French fluency adequate to answer the study questionnaires, and participate in diet instruction, as judged by the enrolling physician. Exclusion Criteria: * Documented specific food allergies, celiac disease. * Co-morbidities that might impact the tolerability of the study diet, e.g., type I diabetes, peptic ulcer disease, etc.
Where it's running
-
University of Manitoba
Winnipeg, Manitoba, Canada Recruiting -
McMaster Children's Hospital
Hamilton, Ontario, Canada Recruiting -
London Health Sciences Centre
London, Ontario, Canada Recruiting -
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada Recruiting -
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, Canada Active not recruiting -
The Hospital for Sick Children
Toronto, Ontario, Canada Active not recruiting
Show 1 more location
-
University of Saskatchewan
Saskatoon, Saskatchewan, Canada Active not recruiting
Study contacts
- Principal investigator: Brian M. Feldman — The Hospital for Sick Children
- Study coordinator: Hayyah Clairman
- Email: hayyah.clairman@sickkids.ca
- Phone: 416-813-7979
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using infrared cameras to help detect juvenile arthritis in kids
This study tests whether infrared thermography can help identify joint inflammation in children with juvenile idiopathic arthritis compared with standard tests.
-
Oral health, saliva bacteria, and disease activity in children with JIA
This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.
-
Olokizumab treatment for children with polyarticular juvenile idiopathic arthritis
This test gives weight-based doses of olokizumab every 4 weeks to see if it helps control polyarticular juvenile idiopathic arthritis and is safe for children aged 2–17.
-
Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea
This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.
-
Understanding pain in juvenile idiopathic arthritis
This project will test whether temperature and pressure pain tests, questionnaires, and blood or saliva samples can help explain pain in kids and teens (ages 9–17) with juvenile idiopathic arthritis.
-
Follow-up care for new cases of polyarthritis in children and young adults
This program will try standardized medical follow-up for children and young adults (≤50) with new-onset JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment-naïve or treated ≤3 months to see if more patients reach disease control or remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.